FDA OKs Merck clot drug

Share this article:

The FDA green-lighted Merck's anti-blood-clot drug vorapaxar, which will go by the brand name Zontivity.

Friday's approval is for reducing the risk of heart attack, stroke and cardiovascular death among patients who have already had a heart attack or have blocked arteries of the leg.

Reuters notes that approval was slow-going because of concerns about bleeding among clinical trial patients.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.

Painkiller maker Acura gets NIH grant

The $300,000 grant will go towards an abuse-deterrent technology.

Biologics have higher psoriatic arthritis adherence

A study of psoriatic arthritis patients found greater adherence among patients whose initial treatment was a biologic, compared to those who started with a non-biologic treatment.